Page 12 - Ohnson Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer Massimiliano Colella joins as global Chief Commercial Officer leading CMR Surgical’s commercial and marketing operations to bring Versius to more hospitals around the worldMassimiliano joins CMR at a time of continued expansion as the second largest soft tissue surgical robotics company, with more than 140 Versius installations and more than 15,000 surgical procedures completedFollowing the recent

In this article, we will take a detailed look at the 15 Stocks ChatGPT Says Will Make Me Rich in 10 Years. For a quick overview of the 5 such stocks, read our article 5 Stocks ChatGPT Says Will Make Me Rich in 10 Years. Picking individual stocks to beat the market is getting harder by the […]

Johnson & Johnson's worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients' claims that J&J talc products caused cancer. The settlements were reached "with a goal to facilitate our pursuit of a consensual prepackaged bankruptcy resolution," Erik Haas said on an investor call. J&J said in October that it was considering a new bankruptcy filing to resolve talc claims.

The company has narrowed its focus on its drugs and medical devices business since it hived off its consumer health unit earlier this year. "We think we're very well positioned, even in spite of what will be the beginning of some biosimilar entrants to Stelara outside the US in mid to second half of 2024," Chief Financial Officer Joseph Wolk told Reuters. J&J, which plans to launch at least 20 new therapies by 2030, said over 10 of its products had the potential to generate more than $5 billion in peak year sales - including newer cancer treatments Talvey and Tecvayli.

(Reuters) -The U.S. Food and Drug Administration (FDA) said on Tuesday it was investigating cancer therapies made by companies such as Gilead Sciences, Johnson & Johnson and Novartis over the risk of hospitalizations and death due to a serious safety issue. The FDA said it had received reports of T-cell malignancies, which refer to a group of blood disorders including lymphomas and leukemias, after treatment with CAR-T therapies or chimeric antigen receptor T-cell therapies. Since 2017, six CAR T-cell therapies have been approved by the FDA and all are for the treatment of blood cancers...